Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FTX-TATEs
- Development stage
- Preclinical
- Lead developer
- Fuzionaire Theranostics
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
FTX-TATEs is a somatostatin receptor (SSTR)-targeted radioligand theranostic program being developed by Fuzionaire Theranostics for the diagnosis and treatment of neuroendocrine tumors (NETs). Developed using the proprietary HetSiFA® platform, FTX-TATEs are designed as 'chemical twin' analogs to the FDA-approved 177Lu-DOTA-TATE (Lutathera). The platform enables the creation of theranostic pairs that combine fluorine-18 (18F) for high-resolution PET imaging with therapeutic radionuclides such as lutetium-177 (177Lu), terbium-161 (161Tb), or actinium-225 (225Ac). By targeting SSTR-expressing cells, the drug delivers ionizing radiation directly to tumor sites for therapy or allows for precise localization via PET imaging for companion diagnostics.
- Other names
- SSTR-targeted radioligandchemical twin analog to 177Lu-DOTA-TATE
02
Targets
SSTR5 (Somatostatin receptor 5)SSTR2 (Somatostatin receptor type 2)SSTR4 (Somatostatin receptor 4)SSTR1 (Somatostatin Receptor Type 1)SSTR3 (Somatostatin receptor 3)
Beyond the preview
Go deeper on FTX-TATEs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FTX-TATEs.